Cited by 124Advanced biosensing and bioanalysis techniquesGold and Silver Nanoparticles Synthesis and ApplicationsSARS-CoV-2 detection and testing

Multiplexed Detection of MicroRNA Biomarkers Using SERS-Based Inverse Molecular Sentinel (iMS) Nanoprobes

Open access
Wang, Hsin-Neng, Crawford, Bridget M., Fales, Andrew M., Bowie, Michelle L., Seewaldt, Victoria L., Vo-Dinh, Tuan·2016·The Journal of Physical Chemistry C

Abstract

MicroRNAs (miRNAs) have demonstrated great promise as a novel class of biomarkers for early detection of various cancers, including breast cancer. However, due to technical difficulties in detecting these small molecules, miRNAs have not been adopted into routine clinical practice for early diagnostics. Thus, it is important to develop alternative detection strategies that could offer more advantages over conventional methods. Here, we demonstrate the application of a "turn-on" SERS sensing technology, referred to as "inverse Molecular Sentinel (iMS)" nanoprobes, as a homogeneous assay for multiplexed detection of miRNAs. This SERS nanoprobe involves the use of plasmonic-active nanostars as the sensing platform. The "OFF-to-ON" signal switch is based on a nonenzymatic strand-displacement process and the conformational change of stem-loop (hairpin) oligonucleotide probes upon target binding. This technique was previously used to detect a synthetic DNA sequence of interest. In this study, we modified the design of the nanoprobe to be used for the detection of short (22-nt) miRNA sequences. The demonstration of using iMS nanoprobes to detect miRNAs in real biological samples was performed with total small RNA extracted from breast cancer cell lines. The multiplex capability of the iMS technique was demonstrated using a mixture of the two differently labeled nanoprobes to detect miR-21 and miR-34a miRNA biomarkers for breast cancer. The results of this study demonstrate the feasibility of applying the iMS technique for multiplexed detection of short miRNAs molecules.

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1021/acs.jpcc.6b03299

Cites

57 of 57 references verified0 citation errors · 0 not checkable

Statistics

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Cites

Flagged first, then by citations

Research works printed but not linked: 2

  1. Fix L. N., 2010, Cancer Genomics-Proteomics, 7, 261
  2. 10.1021/nn800243g · DOI · Paper page

Cited by

Sorted by citations

Authors
Wang, H.-N., Crawford, B. M., Fales, A. M., Bowie, M. L., Seewaldt, V. L., & Vo-Dinh, T.
Affiliations
  • Duke University (US)
  • Department of Biomedical Engineering, ‡Fitzpatrick Institute for Photonics, and ⊥Department of Chemistry, Duke University, Durham, North Carolina 27708, United States
Venue
The Journal of Physical Chemistry C
Published
2016-07-11
Volume
120
Issue
37
Pages
21047-21055
ISSN
  • 1932-7447 (ISSN-L)
  • 1932-7455
OpenAlex
W2468826163
Cited by
124
References
57
Citations by year
2026: 2 · 2025: 1 · 2024: 6 · 2023: 10 · 2022: 15 · 2021: 14 · 2020: 18 · 2019: 26 · 2018: 18 · 2017: 14
FWCI
10.05
Type
journal article
Language
en
Open access
Locations
  • The Journal of Physical Chemistry C (publishedVersion)
  • PubMed (publishedVersion)
  • Europe PMC (PubMed Central) (acceptedVersion)
  • PubMed Central (acceptedVersion)
Funders
  • National Cancer Institute (1 R21 CA196426)
  • Office of Science (DE-SC0014077)
  • Duke Faculty Exploratory Research Fund
Topics
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Advanced biosensing and bioanalysis techniques
  • Physical Sciences › Materials Science › Electronic, Optical and Magnetic Materials › Gold and Silver Nanoparticles Synthesis and Applications
  • Health Sciences › Medicine › Infectious Diseases › SARS-CoV-2 detection and testing
Keywords
microRNA detection, surface-enhanced Raman scattering, multiplexed biomarker detection, miR-21, miR-34a, breast cancer biomarkers, small RNA

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review